Attralus lands $116m Series B

Attralus, Inc., a clinical stage biopharmaceutical company, has secured $116 million in Series B financing.

Attralus, Inc., a clinical stage biopharmaceutical company, has secured $116 million in Series B financing. Logos Capital led the round.

Source: Press Release